NASDAQ · ADMP
Healthcare · Drug Manufacturers - Specialty & Generic
$0.78
Up+$0.01 (+0.85%)
Updated Sep 19, 2026, 11:40 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ADMP does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ADMP.
ADMP research
Company profile and research snapshot.
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 13, 2020 | Maxim Group | Buy | — |
| Nov 26, 2019 | Raymond James | Market Perform | — |
| Nov 25, 2019 | Maxim Group | Hold | — |
| Jul 23, 2019 | B. Riley FBR | Neutral | — |
| Jul 16, 2019 | B. Riley | Sell | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Sep 7, 2023
Company to begin trading under new ticker symbol “DMK” on September 8, 2023 Company to begin trading under new ticker symbol “DMK” on September 8, 2023
GlobeNewswire Inc. · Aug 21, 2023
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.
GlobeNewswire Inc. · Aug 4, 2023
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock. Each unit was sold at a public offering price of $1.35. The common warrants are immediately exercisable at a price of $1.35 per share and expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants were only purchasable together in this offering, but were issued separately and immediately separable upon issuance.
PennyStocks · Aug 4, 2023
Can these tips help you to use analyst ratings to find penny stocks to buy? The post Are Analyst Ratings Important When Trading Penny Stocks? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ADMP.
No results
No recent SID articles mention ADMP.
